For example, recently reported approaches include upregulation of the activating NKG2D NK cell ligands on colon cancer cells, multiple myeloma cells, and hepatocellular carcinoma cells, through administration of spironolactone (SPIR) (307), upregulation of Liver X receptor (308), and inhibition of Enhancer of zeste homolog 2 (EZH2) (309). Here, EZH2 is linked to colonic neoplasm.